NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO) ("Lexeo"), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced the closing of its previously announced underwritten public offering and concurrent private placement, for total gross proceeds to Lexeo of approximately $153.8 million, before deducting underwriting discounts and commission and other expenses payable by Lexeo in connection with the transaction and including the full exercise of the underwriters' option to purchase additional shares.

In the public offering, Lexeo sold 17,968,750 shares of its common stock at $8.00 per share, which includes the full exercise of the underwriters' option to purchase 2,343,750 shares of Lexeo's common stock. The gross proceeds to Lexeo from the public offering, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $143.8 million.

Concurrent with the public offering, Lexeo sold prefunded warrants to purchase 1,250,015 shares of its common stock to Balyasny Asset Management at a price of $7.9999 per pre-funded warrant, in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). The gross proceeds to ...